Latest Share Chat

REMOVE ADS

Glaxosmithkline Regulatory News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes

Get Live Data

1,925.50 2.50 (0.13%)

Bid:

1,931.50

Ask:

1,932.50

Spread: 1.00 (0.052%)

Market Cap: £77.17b

Last checked at -

Intraday Glaxosmithkline Share Chart

REMOVE ADS

Director/PDMR Shareholding

15 Feb 2023 16:04

RNS Number : 0567Q

GSK PLC

15 February 2023

GSK plc (the 'Company')

Vesting of Deferred Bonus Awards under the Deferred Annual Bonus Plan and Sale of Ordinary Shares

This notification sets out the vesting details for Persons Discharging Managerial Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary Shares made in 2020 under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') and subsequent sale of Ordinary Shares to meet tax liabilities. In accordance with the shareholder approved 2017 Remuneration Policy and the DABP rules, the awards comprised a mandatory bonus deferral only. The three-year restricted period for the awards commenced on 14 February 2020 and ended on 14 February 2023. Dividends accrued on the awards during the restricted period. The awards were granted in 2020 as nil-cost options over Ordinary Shares.

The closing price of Ordinary Shares of GSK plc on 14 February 2023 was £14.70.

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	60,707

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8730	28,576

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr I Mackay
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	40,985

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr I Mackay
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8887	19,292

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms D Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	7,893

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms D Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8743	4,240

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr J Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	11,259

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr J Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8628	5,305

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms S Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	4,796

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms S Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8804	2,263

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr L Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	18,375

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr L Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8830	1,171

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D Redfern
b)	Position/status	President Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	13,471

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D Redfern
b)	Position/status	President Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8750	6,348

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	9,539

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8756	4,500

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	7,779

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8772	3,669

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSFFFMIEDSESE

Date		Source	Headline
22nd Feb 2022	2:00 pm	RNS	GSK Consumer Healthcare to be called Haleon
22nd Feb 2022	9:22 am	RNS	Director/PDMR Shareholding
18th Feb 2022	4:30 pm	RNS	Director/PDMR Shareholding
18th Feb 2022	7:00 am	RNS	GSK gives update on RSV maternal vaccine candidate
17th Feb 2022	4:00 pm	RNS	Director/PDMR Shareholding
17th Feb 2022	3:40 pm	RNS	Director/PDMR Shareholding
17th Feb 2022	3:20 pm	RNS	Director/PDMR Shareholding
17th Feb 2022	2:50 pm	RNS	Director/PDMR Shareholding
17th Feb 2022	2:19 pm	RNS	Director/PDMR Shareholding
16th Feb 2022	6:04 pm	RNS	Director/PDMR Shareholding
14th Feb 2022	5:50 pm	RNS	Director/PDMR Shareholding
14th Feb 2022	1:26 pm	RNS	Transfer of Treasury Shares
11th Feb 2022	2:06 pm	RNS	Director/PDMR Shareholding
11th Feb 2022	9:33 am	RNS	Director/PDMR Shareholding
10th Feb 2022	9:00 am	RNS	Benlysta approved in China for Lupus Nephritis
9th Feb 2022	11:07 am	RNS	Director/PDMR Shareholding
9th Feb 2022	7:00 am	RNS	Final Results
7th Feb 2022	10:30 am	RNS	Publication of full year 2021 results: Replacement
7th Feb 2022	10:00 am	RNS	Publication of full year 2021 results
2nd Feb 2022	7:00 am	RNS	GSK announces settlement between ViiV and Gilead
1st Feb 2022	1:44 pm	RNS	FDA approves ViiV Healthcare’s sNDA for Cabenuva
1st Feb 2022	11:44 am	RNS	Total Voting Rights
26th Jan 2022	4:48 pm	RNS	Director/PDMR Shareholding
20th Jan 2022	3:59 pm	RNS	Director/PDMR Shareholding
19th Jan 2022	4:33 pm	RNS	Director/PDMR Shareholding
19th Jan 2022	3:14 pm	RNS	Director/PDMR Shareholding
19th Jan 2022	3:10 pm	RNS	Director/PDMR Shareholding
19th Jan 2022	7:00 am	RNS	Tony Wood appointed CSO Designate, GSK
17th Jan 2022	5:04 pm	RNS	Director/PDMR Shareholding
17th Jan 2022	3:07 pm	RNS	Director/PDMR Shareholding
17th Jan 2022	7:00 am	RNS	Update - GSK Consumer Healthcare
14th Jan 2022	3:22 pm	RNS	Director/PDMR Shareholding
13th Jan 2022	4:12 pm	RNS	Director/PDMR Shareholding
11th Jan 2022	4:28 pm	RNS	Director/PDMR Shareholding
11th Jan 2022	12:08 pm	RNS	US Govt buys additional 600,000 sotrovimab doses
4th Jan 2022	12:28 pm	RNS	Total Voting Rights
23rd Dec 2021	1:11 pm	RNS	Director/PDMR Shareholding
22nd Dec 2021	2:57 pm	RNS	Director/PDMR Shareholding
21st Dec 2021	7:00 am	RNS	ViiV Healthcare announces FDA approval of Apretude
20th Dec 2021	7:00 am	RNS	Consumer Healthcare Chair Designate appointed
17th Dec 2021	12:48 pm	RNS	Xevudy approved in Europe to treat COVID-19
15th Dec 2021	7:00 am	RNS	GSK/Sanofi COVID-19 vaccine booster & Ph3 update
13th Dec 2021	11:25 am	RNS	Director/PDMR Shareholding
9th Dec 2021	4:35 pm	RNS	Director/PDMR Shareholding
7th Dec 2021	12:00 pm	RNS	Medicago/GSK COVID-19 vaccine positive Ph3 data
7th Dec 2021	7:07 am	RNS	Sotrovimab retains its activity vs Omicron variant
2nd Dec 2021	7:02 am	RNS	Sotrovimab retains its activity vs Omicron variant
1st Dec 2021	11:05 am	PRN	Total Voting Rights
24th Nov 2021	4:17 pm	RNS	Director/PDMR Shareholding
24th Nov 2021	4:00 pm	RNS	GSK publishes provisional 2022 dividend dates

Latest Share Chat

Glaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

Please enter at least 2 characters

No results found

Search results

Trending